Preclinical, Publications Suppression of PD-L1 expression by a novel liver-targeted siRNA leads to potential restoration of immune responses against HBV
ALG-097558 Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development
ALG-097558, Publications Mutations L50F, E166A and L167F in SARS-CoV-2 3CLpro are Selected by a Protease Inhibitor In Vitro and are Associated with Resistance
Preclinical, Publications SARS-CoV-2 Viruses with Cross-Resistance to 3CLpro Inhibitors can be Selected In Vitro, and can Replicate and Transmit in a Hamster Model
ALG-097558, Publications Discovery of ALG-097558, a Novel 3CL Protease Inhibitor with Activity in the SARS-CoV-2 Hamster Infection Model
ALG-097558, Publications Discovery and Antiviral Activity of the Novel 3CL Protease Inhibitor ALG-097558 in the SARS-CoV-2 Hamster Infection Model
ALG-055009, Publications Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia